Intravitreal dexamethasone implant in the treatment of pseudophakic cystoid macular edema or irvine-gass syndrome

Simple item page
dc.authorscopusid55755921600
dc.authorscopusid35301469100
dc.authorscopusid45161508200
dc.authorscopusid57218937688
dc.authorscopusid55246846900
dc.contributor.authorKaldirim H.
dc.contributor.authorYazgan S.
dc.contributor.authorKirgiz A.
dc.contributor.authorKürşat A.
dc.contributor.authorNacaroğlu Ş.A.
dc.date.accessioned2024-08-04T20:01:00Z
dc.date.available2024-08-04T20:01:00Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: To evaluate the effectiveness of intravitreal injections of dexamethasone (DEX) implant in patients with pseudophakic cystoid macular edema (PCME) or Irvine-Gass Syndrome (IGS). Material and Methods: Patients with ME secondary to uncomplicated cataract surgery who underwent single intravitreal injections of DEX implant from January 2015 to January 2017 were retrospectively reviewed. The patients were examined at base-line and day 1, week 1, month 1, 3, 6 and 12 after intravitreal injection. All patients underwent a complete ophthalmic evaluation, including biomicroscopy, best-corrected visual acuity (BCVA), intraocular pressure by applanation tonometry, and central macular thickness (CMT) measurement with a spectral-domain optical coherence tomography (SD-OCT). Results: Nineteen eyes of 18 patients were evaluated. The alteration of mean BCVA and CMT were statistically significantly better than baseline values at first, third, sixth and twelfth months (p< 0.001). At 1st week, 1st month and 3rd month intraocular pressure (IOP) values significantly higher than baseline (p=0.001, p=0.006, p=0.001, respectively). At 6th month and 12th month IOP values not significantly different at baseline (p=0.506, p=0.650). Conclusion: Both BCVA and mean CMT had significantly improved from baseline values after treatment with single doz intravitreal DEX implant in patients with IGS. © 2020 Gazi Eye Foundation. All rights reserved.en_US
dc.identifier.doi10.37845/RET.VIT.2020.29.19
dc.identifier.endpage110en_US
dc.identifier.issn1300-1256
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85090849560en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage105en_US
dc.identifier.urihttps://doi.org/10.37845/RET.VIT.2020.29.19
dc.identifier.urihttps://hdl.handle.net/11616/91168
dc.identifier.volume29en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGazi Eye Foundationen_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIntravitreal dexamethasone implanten_US
dc.subjectIrvine-gass syndromeen_US
dc.subjectPseudophakic cystoid macular edemaen_US
dc.titleIntravitreal dexamethasone implant in the treatment of pseudophakic cystoid macular edema or irvine-gass syndromeen_US
dc.typeArticleen_US

Files

Collections

Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize